May 5, 2026 – Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and the TSC Alliance, an internationally recognized nonprofit that improves quality of life for everyone affected by tuberous sclerosis complex (TSC), today announced a collaboration to advance gene therapy programs designed to treat tuberous sclerosis complex (TSC), a rare genetic disease. Gene therapy programs advanced through the collaboration will use Apertura’s TfR1 CapX™, a novel, intravenously delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1), cross the blood-brain barrier, and enable broad distribution to the brain and spinal cord.